Equities Analysts Set Expectations for RDY FY2027 Earnings

Key Points

• Zacks Research raised its FY2027 earnings forecast for Dr. Reddy’s Laboratories to $0.44 per share from $0.43, still below the broader consensus estimate of $0.46.
• Analyst opinions are mixed, but the stock carries a consensus Hold rating, based on two Buy, three Hold, and one Sell recommendation.
• The company beat its latest quarterly estimates, reporting $0.12 EPS versus $0.10 expected and revenue of $903.89 million versus $894.94 million expected.

Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) - Stock analysts at Zacks Research boosted their FY2027 EPS estimates for shares of Dr. Reddy's Laboratories in a research report issued on Friday, November 6th. Zacks Research analyst Team now expects that the company will post earnings of $0.44 per share for the year, up from their previous estimate of $0.43. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $0.46 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' Q4 2027 earnings at $0.10 EPS, Q3 2028 earnings at $0.15 EPS, Q4 2028 earnings at $0.14 EPS, FY2028 earnings at $0.53 EPS and FY2029 earnings at $0.65 EPS.

Several other equities analysts have also weighed in on the company. JPMorgan Chase & Co. raised Dr. Reddy's Laboratories from an "underweight" rating to a "neutral" rating in a research note on Monday, October 26th. BNP Paribas Exane raised Dr. Reddy's Laboratories to an "outperform" rating and set a $14.80 price target for the company in a research note on Monday, October 12th. Wall Street Zen raised Dr. Reddy's Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, October 17th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Dr. Reddy's Laboratories in a research report on Wednesday, October 21st. Finally, Jefferies Financial Group upgraded shares of Dr. Reddy's Laboratories from an "underperform" rating to a "hold" rating and set a $13.90 price target on the stock in a research report on Sunday, October 25th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $492.90.

Dr. Reddy's Laboratories Trading Down 0.1%

NYSE RDY opened at $14.89 on Monday. The stock has a 50-day simple moving average of $12.77 and a 200 day simple moving average of $13.25. The company has a market capitalization of $12.43 billion, a PE ratio of 40.25, a P/E/G ratio of 3.09 and a beta of 0.31. The company has a current ratio of 1.93, a quick ratio of 1.40 and a debt-to-equity ratio of 0.03. Dr. Reddy's Laboratories has a 12 month low of $11.36 and a 12 month high of $15.67.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Saturday, October 24th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.02. Dr. Reddy's Laboratories had a return on equity of 7.91% and a net margin of 8.56%. The company had revenue of $903.89 million for the quarter, compared to the consensus estimate of $894.94 million.

Hedge Funds Weigh In On Dr. Reddy's Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada raised its stake in Dr. Reddy's Laboratories by 4.6% during the 1st quarter. Royal Bank of Canada now owns 9,984,082 shares of the company's stock worth $138,293,000 after buying an additional 434,805 shares during the period. Aikya Investment Management Ltd lifted its holdings in Dr. Reddy's Laboratories by 6.8% during the third quarter. Aikya Investment Management Ltd now owns 9,068,536 shares of the company's stock worth $114,445,000 after acquiring an additional 574,684 shares in the last quarter. Bessemer Group Inc. grew its stake in Dr. Reddy's Laboratories by 28.4% in the first quarter. Bessemer Group Inc. now owns 1,823,285 shares of the company's stock valued at $25,253,000 after acquiring an additional 403,219 shares during the period. Quantinno Capital Management LP grew its stake in Dr. Reddy's Laboratories by 71.2% in the first quarter. Quantinno Capital Management LP now owns 637,094 shares of the company's stock valued at $8,824,000 after acquiring an additional 264,856 shares during the period. Finally, B. Metzler seel. Sohn & Co. AG grew its stake in Dr. Reddy's Laboratories by 18.9% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 434,529 shares of the company's stock valued at $6,296,000 after acquiring an additional 69,044 shares during the period. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes.

Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.

Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.